JP2005523269A - 老人性うつ病の治療におけるカルニチン - Google Patents

老人性うつ病の治療におけるカルニチン Download PDF

Info

Publication number
JP2005523269A
JP2005523269A JP2003565465A JP2003565465A JP2005523269A JP 2005523269 A JP2005523269 A JP 2005523269A JP 2003565465 A JP2003565465 A JP 2003565465A JP 2003565465 A JP2003565465 A JP 2003565465A JP 2005523269 A JP2005523269 A JP 2005523269A
Authority
JP
Japan
Prior art keywords
carnitine
acid
pharmaceutically acceptable
use according
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003565465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523269A5 (https=
Inventor
ジェイ・ダブリュー・ペティグリュー
サミュエル・ガーション
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2005523269A publication Critical patent/JP2005523269A/ja
Publication of JP2005523269A5 publication Critical patent/JP2005523269A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003565465A 2002-02-07 2003-01-23 老人性うつ病の治療におけるカルニチン Pending JP2005523269A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35432302P 2002-02-07 2002-02-07
PCT/IT2003/000023 WO2003066041A1 (en) 2002-02-07 2003-01-23 Carnitine in the treatment of geriatric depression

Publications (2)

Publication Number Publication Date
JP2005523269A true JP2005523269A (ja) 2005-08-04
JP2005523269A5 JP2005523269A5 (https=) 2006-03-09

Family

ID=27734357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003565465A Pending JP2005523269A (ja) 2002-02-07 2003-01-23 老人性うつ病の治療におけるカルニチン

Country Status (10)

Country Link
US (1) US20040009926A1 (https=)
EP (1) EP1471904A1 (https=)
JP (1) JP2005523269A (https=)
KR (1) KR20040083471A (https=)
AR (1) AR038350A1 (https=)
AU (1) AU2003219511A1 (https=)
CA (1) CA2469925A1 (https=)
MX (1) MXPA04007506A (https=)
PL (1) PL374082A1 (https=)
WO (1) WO2003066041A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025530455A (ja) * 2022-09-23 2025-09-11 合肥瀚微生物科技有限公司 うつ病を治療又は緩和するための４－ｔｍａｐの使用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407778B2 (en) 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US20050272812A1 (en) * 2002-02-07 2005-12-08 Pettegrew Jay W Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans
US7815894B2 (en) 2003-05-29 2010-10-19 Jay W. Pettegrew Compounds, compositions and methods for medical imaging of neuropsychiatric disorders
MX2012014127A (es) 2010-06-16 2013-06-28 Sigma Tau Ind Farmaceuti Acetil-carnitina para uso en un metodo para incrementar neurogenesis en tejido nervioso.
EP3212191B1 (en) * 2014-10-28 2022-10-05 Medlab IP Pty Ltd. Treatment for depression and depressive disorders
US11918336B2 (en) * 2019-02-19 2024-03-05 King Abdullah University Of Science And Technology Reduced feature generation for signal classification based on position weight matrix
KR20230011999A (ko) 2020-05-15 2023-01-25 알파시그마 에스.피.에이. 메틸폴레이트를 포함하는 조성물
CA3238205A1 (en) * 2021-11-12 2023-05-19 Rajaram Samant A synergistic composition for activating intracellular secondary messenger(camp) pathway

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5879884A (en) * 1994-12-29 1999-03-09 Peroutka; Stephen J. Diagnosis of depression by linkage of a polymorphic marker to a segment of chromosome 19P13 bordered by D19S247 and D19S394
JP3425276B2 (ja) * 1995-08-11 2003-07-14 株式会社日立製作所 情報通知システム
JPH10143640A (ja) * 1996-11-15 1998-05-29 Nippon Lsi Card Kk 携帯コンピュータ及びそれを用いた情報管理システム並びにそれを用いた立体地図の作成方法
US5889055A (en) * 1997-04-04 1999-03-30 Howard; James R. L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025530455A (ja) * 2022-09-23 2025-09-11 合肥瀚微生物科技有限公司 うつ病を治療又は緩和するための４－ｔｍａｐの使用

Also Published As

Publication number Publication date
CA2469925A1 (en) 2003-08-14
AR038350A1 (es) 2005-01-12
AU2003219511A1 (en) 2003-09-02
US20040009926A1 (en) 2004-01-15
EP1471904A1 (en) 2004-11-03
KR20040083471A (ko) 2004-10-02
PL374082A1 (en) 2005-09-19
MXPA04007506A (es) 2004-11-10
WO2003066041A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
Willemsen et al. Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome
Kato et al. Choline-containing compounds detected by proton magnetic resonance spectroscopy in the basal ganglia in bipolar disorder
AU2005204358B2 (en) Memantine for the treatment of mild and mild-to-moderate Alzheimer's disease
ES2245037T3 (es) Utiizacion de compuestos que contienen citidina y que contienen citosina para el tratamiento de la exposicion a estimulantes.
JP2021527090A (ja) 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物
JP2005523269A (ja) 老人性うつ病の治療におけるカルニチン
JP2001503731A (ja) グルタメート仲介疾患の処置のためアルカノイル―ｌ―カルニチンの使用
JPH09323927A (ja) 慢性閉塞性動脈硬化症の治療のためのカルニチン誘導体含有薬剤
Graham et al. Magnetic resonance spectroscopy of N‐acetylaspartate in hypoxic–ischemic encephalopathy
US7956091B2 (en) Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
JP2011116775A (ja) 局所脳血流低下に伴う神経系障害の予防または治療のための医薬組成物
AU2011285703B2 (en) Methods and pharmaceutical compositions for treating adverse or deleterious sequellae of traumatic brain injury
JPH0657654B2 (ja) 患者の疲労減少用組成物
KR20200121819A (ko) 하지 불안 증후군을 치료하기 위한 치료제
US8013016B2 (en) Use of acetyl L-carnitine for the treatment of fibromyalgic syndrome
US7776913B2 (en) Carnitines for treating or preventing disorders caused by andropause
EP1399143B1 (en) Use of acetyl l-carnitine for the preparation of a medication to treat anhedonia
RU2506950C2 (ru) Комбинация карбостирила и карнитина
JP5685362B2 (ja) 有痛性末梢糖尿病性神経障害の予防のためのアセチルｌ−カルニチン
Kourtopoulos Issue 5 th-Article 7 th

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090825

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100216